EGFR and lung cancer: In EGFR-mutant lung cancer, LINC00460 promotes EGFR-TKI resistance, and patients with high LINC00460 expression who receive gefitinib therapy have a lower five-year OS rate than do patients with low LINC00460 expression (Nakano et al., 2020).